GSK plc
GSK plc is a global biopharma company that develops and commercializes prescription medicines, vaccines, and specialty treatments. Its business is organized around research, development, manufacturing, and global distribution across major markets, with a material presence in the United Kingdom, the United States, and other international regions.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenuePreventive vaccines sold to public health systems, governments, and private providers.
Prescription medicines for infectious diseases, HIV, respiratory, immunology, and oncology.
Established medicines and branded treatments used in primary care and select specialist settings.
Development-stage products and acquired assets that may not yet generate commercial revenue.
Customers
GSK sells primarily to healthcare systems, hospitals, clinics, pharmacies, and government buyers that procure medicines and vaccines for patient treatment and public immunization programs. It also serves specialist physicians and managed-care channels that influence prescribing and reimbursement for complex therapies. In the U.S., commercial and government reimbursement arrangements are especially important because rebates and chargebacks affect realized net sales.
Buy vaccines and essential medicines for national immunization and treatment programs.
Hospitals, clinics, and specialist centers that administer prescription therapies.
Purchase branded medicines for downstream dispensing to patients.
Influence realized sales through rebates, chargebacks, and access decisions.
Physicians who drive use of HIV, respiratory, immunology, and oncology products.
Strategy
GSK's strategy centers on using science, technology, and internal R&D to build a pipeline of differentiated medicines and vaccines. It also relies on acquisitions and asset development to expand specialty medicine capabilities and deepen long-term commercial opportunities. Maintaining access to major reimbursement systems and progressing assets through regulatory approval are central to its competitive position.
Approved products are the main route to future commercial revenue and scale.
Specialty therapies can create durable demand in complex chronic diseases.
Vaccines provide large-scale public health relevance and diversified demand.
Geography
GSK is a multinational business with sales, R&D, and commercial operations across North America, Europe, and other international markets. The company has a particularly important U.S. footprint, while the UK remains central as its corporate base and operating hub. Geography matters because reimbursement, pricing, and regulatory frameworks differ significantly by country and affect both demand access and net realized revenue.
Risks
GSK faces the usual pharmaceutical risks around clinical trial failure, regulatory delays, and competition from alternative therapies. Its U.S. business is also exposed to rebate, chargeback, and return-related gross-to-net deductions, which can move reported revenue materially from period to period. Acquired development assets add execution risk because they may remain loss-making until approval and commercial launch.
- Gross-to-net revenue volatility in the U.S.Impact: HighLikelihood: High
Rebates, chargebacks, and returns reduce recognized revenue and are judgmental estimates.
Exposure: Commercial and government reimbursement contracts
- Competition and pricing pressureImpact: HighLikelihood: High
Large pharma markets are crowded and access decisions can constrain uptake.
Exposure: Vaccines and specialty medicines
- Pipeline and regulatory riskImpact: HighLikelihood: Medium
Drug candidates only generate value if trials succeed and approvals are obtained.
Exposure: R&D portfolio and acquired development assets
- Integration and commercialization risk for acquired assetsImpact: MediumLikelihood: Medium
Development-stage assets may take time to integrate and monetize after acquisition.
Exposure: RAPT and 35Pharma acquired assets
Accounting
Judgemental itemsRebates, chargebacks, and returns change reported net revenue and can fluctuate by period.
Impact: Affects top-line comparability and gross-to-net margins
Large acquisitions add intangible assets and goodwill that require impairment testing.
Impact: Can lead to non-cash write-downs if asset values weaken
Fair values for recent acquisitions are preliminary and may be revised later.
Impact: Can alter the balance sheet and future amortization
Acquired pipeline assets may not generate revenue until regulatory approval.
Impact: Affects earnings timing and R&D-related asset recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Gilead Sciences, Inc
GILD · Biological Products, (No Diagnostic Substances)
Gilead Sciences is a U.S.-based biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious diseases.
Sanofi
SNY · Pharmaceutical Preparations
Sanofi is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines and vaccines.
Pfizer, Inc
PFE · Pharmaceutical Preparations
Merck & Co., Inc.
MRK · Pharmaceutical Preparations
AstraZeneca PLC
AZN · Pharmaceutical Preparations
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Last updated: 28/09/2026